BamSEC and AlphaSense Join Forces
Learn More

Enliven Therapeutics Inc. – Material Contracts

NASDAQ: ELVN    
Share price (5/22/26): $41.54    
Market cap (5/22/26): $2.530 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.25
from 10-K 12 pages Enliven Therapeutics, Inc. Amended and Restated 2020 Equity Incentive Plan Notice of Restricted Stock Unit Award and Restricted Stock Unit Agreement
12/34/56
EX-10.24
from 10-K 5 pages Enliven Therapeutics, Inc. Stock Option Agreement
12/34/56
EX-10.18
from 10-K 6 pages Enliven Therapeutics, Inc. Outside Director Compensation Policy Adopted and Approved February 23, 2023 as Amended Effective January 1, 2026 (The “Effective Date”) 1. Cash Compensation Additional Annual Cash Retainers for Service as Committee Chair and Committee Member Audit Committee Chair: $20,000 Member of Audit Committee: $10,000 Compensation Committee Chair: $15,000 Member of Compensation Committee: $7,500 Nominating and Corporate Governance Committee Chair: $10,000 Member of Nominating and Corporate Governance Committee: $5,000
12/34/56
EX-10.16
from 10-K 29 pages [###] Certain Exhibits or Schedules to This Exhibit Have Been Omitted in Compliance With Regulation S-K Item 601(a)(5). [***] Portions of This Exhibit Have Been Redacted in Compliance With Regulation S-K Item 601(a)(6). [†††] Pursuant to Item 601(b)(10) of Regulation S-K, Certain Information Contained in This Document, Marked by Brackets, Has Been Omitted Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Transition Agreement and Release
12/34/56
EX-10.3
from 8-K 17 pages Enliven Therapeutics, Inc. 2025 Inducement Equity Incentive Plan
12/34/56
EX-10.2
from 8-K 11 pages Enliven Therapeutics, Inc. Change in Control and Severance Agreement
12/34/56
EX-10.1
from 8-K 5 pages Certain Exhibits or Schedules to This Exhibit Have Been Omitted in Compliance With Regulation S-K Item 601(a)(5). [***] Portions of This Exhibit Have Been Redacted in Compliance With Regulation S-K Item 601(a)(6)
12/34/56
EX-10.16
from 10-K 6 pages Enliven Therapeutics, Inc. Outside Director Compensation Policy Adopted and Approved February 23, 2023 as Amended January 1, 2025 (The “Effective Date”) 1. Cash Compensation Additional Annual Cash Retainers for Service as Committee Chair and Committee Member Audit Committee Chair: $15,000 Member of Audit Committee: $7,500 Compensation Committee Chair: $12,000 Member of Compensation Committee: $6,000 Nominating and Corporate Governance Committee Chair: $10,000 Member of Nominating and Corporate Governance Committee: $5,000
12/34/56
EX-10.1
from 8-K 12 pages Enliven Therapeutics, Inc. Amended and Restated 2020 Equity Incentive Plan
12/34/56
EX-10.1
from 8-K 44 pages [***] Portions of This Exhibit Have Been Redacted in Compliance With Regulation S-K Item 601(a)(6). Enliven Therapeutics, Inc. Securities Purchase Agreement Agreement
12/34/56
EX-10.16
from 10-K 6 pages Enliven Therapeutics, Inc. Outside Director Compensation Policy Adopted and Approved February 23, 2023 as Amended February 13, 2024 (The “Effective Date”) 1. Cash Compensation Additional Annual Cash Retainers for Service as Committee Chair and Committee Member Audit Committee Chair: $15,000 Member of Audit Committee: $7,500 Compensation Committee Chair: $10,000 Member of Compensation Committee: $5,000 Nominating and Corporate Governance Committee Chair: $8,000 Member of Nominating and Corporate Governance Committee: $4,000
12/34/56
EX-10.15
from 10-K 11 pages Amended and Restated Change in Control and Severance Agreement
12/34/56
EX-10.14
from 10-K 11 pages Amended and Restated Change in Control and Severance Agreement
12/34/56
EX-10.13
from 10-K 11 pages Amended and Restated Change in Control and Severance Agreement
12/34/56
EX-10.12
from 10-K 11 pages Amended and Restated Change in Control and Severance Agreement
12/34/56
EX-10.11
from 10-K 11 pages Amended and Restated Change in Control and Severance Agreement
12/34/56
EX-10.10
from 10-K 6 pages [***] Portions of This Exhibit Have Been Redacted in Compliance With Regulation S-K Item 601(a)(6) Enliven Therapeutics, Inc. Confirmatory Employment Letter, as Amended and Restated
12/34/56
EX-10.9
from 10-K 6 pages [***] Portions of This Exhibit Have Been Redacted in Compliance With Regulation S-K Item 601(a)(6) Enliven Therapeutics, Inc. Confirmatory Employment Letter, as Amended and Restated
12/34/56
EX-10.8
from 10-K 6 pages [***] Portions of This Exhibit Have Been Redacted in Compliance With Regulation S-K Item 601(a)(6) Enliven Therapeutics, Inc. Confirmatory Employment Letter, as Amended and Restated
12/34/56
EX-10.7
from 10-K 6 pages [***] Portions of This Exhibit Have Been Redacted in Compliance With Regulation S-K Item 601(a)(6) Enliven Therapeutics, Inc. Confirmatory Employment Letter, as Amended and Restated
12/34/56